Review Article

Autism: A “Critical Period” Disorder?

Jocelyn J. LeBlanc and Michela Fagiolini

Harvard Medical School and The F. M. Kirby Neurobiology Center, Children's Hospital Boston, Boston, MA 02115, USA

Correspondence should be addressed to Michela Fagiolini, michela.fagiolini@childrens.harvard.edu

Received 5 March 2011; Accepted 2 June 2011

Academic Editor: Evelyne Sernagor

Copyright © 2011 J. J. LeBlanc and M. Fagiolini. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cortical circuits in the brain are refined by experience during critical periods early in postnatal life. Critical periods are regulated by the balance of excitatory and inhibitory (E/I) neurotransmission in the brain during development. There is now increasing evidence of E/I imbalance in autism, a complex genetic neurodevelopmental disorder diagnosed by abnormal socialization, impaired communication, and repetitive behaviors or restricted interests. The underlying cause is still largely unknown and there is no fully effective treatment or cure. We propose that alteration of the expression and/or timing of critical period circuit refinement in primary sensory brain areas may significantly contribute to autistic phenotypes, including cognitive and behavioral impairments. Dissection of the cellular and molecular mechanisms governing well-established critical periods represents a powerful tool to identify new potential therapeutic targets to restore normal plasticity and function in affected neuronal circuits.

1. Introduction

The developing brain is remarkably malleable, capable of restructuring synaptic connections in response to changing experiences. The basic layout of the brain is first established by genetic programs and intrinsic activity and is then actively refined by the surrounding environment in which the individual is immersed [1]. This experience-dependent sculpting of neuronal circuits occurs during distinct time windows called critical periods [2]. There are thought to be independent postnatal critical periods for different modalities, ranging from basic visual processing to language and social skills. They occur sequentially in a hierarchical manner, beginning in primary sensory areas. Critical periods close after a cascade of structural consolidation of neuronal circuits and their connectivity, preventing future plasticity as the brain reaches adulthood.

These sensitive periods of elevated plasticity are times of opportunity but also of great vulnerability for the developing brain. As many have experienced, it is easier to learn a new language, musical instrument, or sport as a child rather than in adulthood. On the other hand, early disruption of proper sensory or social experiences will result in miswired circuits that will respond suboptimally to normal experiences in the future. The devastating effects of early deprivation are scientifically documented [3, 4]. Studies of socially and emotionally deprived children raised in Romanian orphanages have demonstrated that the neglected children exhibit severe developmental delay, mental retardation, and neuropsychiatric symptoms [4]. Orphans need to be placed with caring foster families away from orphanages before two years of age in order to develop cognitive, social, and intellectual skills. Neglected children are not able to recover normal function even if they are later placed in similar foster homes. Comparable effects are seen for the development of the primary senses as well. Conductive hearing loss often associated with childhood ear infections can produce long-lasting deficits in auditory perceptual acuity if not treated before the age of seven [5–7]. Similarly, if a child's binocular vision is compromised by strabismus or cataract and is not corrected before the age of eight, loss of acuity in that eye, or amblyopia, is permanent and irreversible [8, 9]. If corrected promptly, restoration of normal binocular vision is possible.

Why the brain is able to recover function early in life, but loses this ability with maturity? What are the mechanisms underlying experience-dependent circuit refinement in early development? Can we recreate the plasticity of the immature brain later in life and eventually recover proper
function? It turns out that a very precise balance of cortical excitatory and inhibitory (E/I) neurotransmission is required for critical period plasticity [10, 11]. Studies in the rodent visual system have shown that, in particular, the level of the inhibitory neurotransmitter GABA and the maturation of specific inhibitory circuits are crucial [11, 12]. Since critical periods are so tightly regulated, this makes them vulnerable if the E/I balance is tipped in either direction without compensatory homeostatic correction. Recent research has indicated that neurodevelopmental disorders like autism may result from disruption of this balance early in life. This could be due to a combination of genetic or environmental insults that compromise excitatory or inhibitory components at the genetic, molecular, synaptic, or circuit level. Depending on the location and severity of imbalance, a spectrum of phenotypes could result, as is true for autism. Thus, it is attractive to hypothesize that autism may result from disruption of the expression and/or timing of critical periods across brain regions.

Autism is generally diagnosed within the first three years of life, during this time of intense experience-dependent circuit refinement. The diagnostic behavioral symptoms of autism are abnormal socialization and communication, and repetitive behaviors [13]. Many studies have focused on addressing how the autistic brain perceives relevant information, like face-processing, language, and theory of mind. These data have been valuable in beginning to understand how the higher-order processing centers of the brain differ in autism. However, it is important to realize that these areas rely on integration of inputs from lower cortical regions, building off a reliable and accurate representation of the world generated by primary sensory areas. Critical period disruption resulting in a slight degradation in the quality of any or all of these senses would compromise the ability to successfully execute behaviors relying on this information, creating severe deficits. Indeed, sensory deficits have been reported in autistic individuals, indicating possible improper primary sensory perception [14].

Autism is called a “spectrum disorder” because of the extraordinary heterogeneity of intellectual ability, associated symptoms, and possible etiology. Though there is clearly a genetic basis to autism, the majority of cases have unknown causes [15, 16] Autism is comorbid with a number of other diseases, including Rett, Fragile X, and Angelman Syndrome. These diseases have known genetic causes and have been well modeled via genetic modification of animals, thereby providing valuable tools to dissect the molecular changes underlying autism. Despite these advances, there is still no cure [17, 18].

A common emerging theme based on data from human patients and animal models is an imbalance in excitatory and inhibitory transmission. This review will summarize the research to date that supports this theory, focusing in particular on the disruption of inhibitory signaling and how this may compromise the expression of critical periods, ultimately leading to the characteristic behaviors of autism. With better understanding of the molecular changes in the autistic brain, we can begin to identify key experiments that will help guide therapeutic intervention.

2. Primary Sensory Function in Autism

The majority of autism research has focused on the higher cognitive symptoms of autism, for it is solely these features that comprise the diagnosis of autism. However, it must be considered that the development and proper execution of higher cognitive processes depends on normal primary processing [19]. The behaviors relevant to autism require concurrent information from many sensory areas. For example, communication and socialization involve parallel auditory, visual, and somatosensory information processing. It is interesting to consider a model in which defects in the development of primary sensory abilities are the original problem, which then results in a cascading effect on higher integrative areas of the brain [20].

A common feature of autistic individuals is atypical behavioral responses to sensory stimulation and reports of hyper- or hyposensitivity to sensory stimulation in multiple domains [14, 21]. There are many accounts of disruption of primary sensory processing in autism [22–25], and there is a growing body of evidence that tests these reports in a controlled laboratory setting. A recent meta-analysis of 14 parent-report studies on sensory-modulation suggests that autistic individuals exhibit significantly more sensory symptoms than control groups, particularly between the ages of six and nine [26]. Interestingly, most studies have concluded that several sensory processing are more commonly disrupted in autism than in other developmental disorders; these symptoms lessen with age; their severity correlates with the severity of social impairment [27]. We will touch on a few examples of altered sensory processing in the auditory, somatosensory, visual, and multisensory integration areas from the human autism literature.

Many studies of sensory phenotypes in autism have focused on the auditory system because of the language deficits characteristically observed in patients. There do appear to be lower-level cortical auditory processing abnormalities as measured by electroencephalograms (EEG) and magnetoencephalography (MEG) in multiple studies, but the nature of these differences is variable and depends on the specifics of the individual studies [14]. For example, while some studies have found that autistic subjects have increased latency in cortical response to tones [28, 29], others observed a decreased latency in cortical response [30–32]. These contrasting results may reflect the wide spectrum of autism phenotypes, the limited number of tested subjects, their age, or different experimental paradigms used.

Abnormal somatosensory experiences are commonly reported in autistic individuals [33]. One psychophysical study by Tommerdahl et al. [34] tested the ability to spatially discriminate two vibrotactile stimuli applied to the skin of the hand in a small group of autistic subjects. After a priming stimulus, subsequent spatial discrimination in that same area of skin improved for controls but not for autistic subjects. The authors suggest that this may reflect a deficit in cortical inhibition of neighboring minicolumns, though this claim was not directly tested. Psychophysical studies rely on the behavioral report of the subject, and therefore may be complicated by behavioral impairments in autistic subjects.
Several somatosensory studies have measured brain activity instead as a means to evaluate sensory processing. Miyazaki et al. [35] found abnormal short-latency somatosensory evoked potentials (S-SEPs) in response to median nerve stimulation in about half of the autistic patients they tested. However, it must be noted that there were no concurrent controls tested in this study, and instead autistic S-SEPs were compared to S-SEPs from controls in a previous study. Another group used MEG to map the cortical representation of the hand and face regions of high-functioning autistic and control subjects [36]. Brain activity was recorded in response to physical stimulation of the skin. Interestingly, the autistic subjects had a spatially distorted cortical representation of the hand and face compared with controls. Overall, abnormal somatosensory processing may play a large role in the avoidance of affective contact that contributes to the social and communication abnormalities in autism [33].

Due to the social phenotype of autism, one of the better-studied visual impairments of autism is face processing [27]. However, an interesting hypothesis is that lower-order visual deficits would consequently impair higher-order visual processing of faces. A study by Vlamings et al. [37] recorded VEPs in autistic and control children while they looked at two types of stimuli—simple horizontal gratings or faces with neutral or fearful expressions. The gratings or faces were composed of either high or low spatial frequency lines. Autistic children, in contrast to controls, had an enhanced VEP response to high spatial frequencies and performed better at facial expression categorization when the faces were high-pass filtered. Nonautistic children generally use low spatial frequency information to categorize the emotions of facial expressions. This difference seen in autistic children is in agreement with previous findings that autistic perception is more detail-oriented [38–41]. This study suggests that abnormal primary visual processing could also contribute to social and communicative deficits in autism.

In addition to atypical unisensory experiences in autism, growing evidence points towards abnormalities in multisensory processing, which is the integration of information from different senses into one perceptual experience [14]. Deficits in multisensory integration (MSI) fit with a popular theory of the autistic brain, in which there is excessive local connectivity within one brain region but long-range hyperconnectivity between brain regions [19, 42, 43]. As for unisensory modality processing, MSI seems to be disrupted in a variety of ways depending on the study, including enhanced, decreased, or altered in some fashion. A recent study used high-density electrical mapping of the cortex with EEG to measure MSI in response to audio-somatosensory stimuli [44]. Vibrotactile stimulation and tones were presented to the passive subject either separately or in combination, and differences in event-related potentials (ERPs) between uni- and multimodal stimulation were measured. Overall, the autism group showed less MSI than controls. In contrast, a psychophysical study investigated audio-visual integration, as this has direct relevance to speech perception, and found an extended temporal window for MSI in the autism group [45].

Another way to evaluate audio-visual integration is with the McGurk effect [46]. In the McGurk effect paradigm, an individual hears the sound of one phoneme (/ba/) while watching a muted video of a person saying another phoneme (/ga/). Due to the multimodal quality of speech perception, the sound of the voice combines with the sight of the lips moving, and the individual reports hearing a third intermediate phoneme (e.g., /da/), the perceptual product of normal multimodal integration. This phenomenon was originally reported to occur less frequently for autistic individuals [47]. More recent studies confirmed some level of disruption in the McGurk paradigms in autism subjects mainly affecting the ability to read lips [48, 49] and the comprehension of speech in the presence of background noise compared to control subjects [49]. Audiovisual speech integration is already present in infants as young as 2 months old [50] and contributes to phonetic learning [51] and language development [52]. Combined deficits in audiovisual processing may then contribute to delays in language acquisition and speech comprehension during social interactions or school settings.

In order to better understand the role of sensory processing and perception in the pathogenesis of autism, a systematic developmental study must be conducted in autistic, high-risk infant siblings and control subjects. The development of primary senses, as well as their integration into meaningful behavior, requires experience-dependent plasticity. We propose that a disruption of neuronal circuit refinement during critical periods may represent the mechanistic link between these abnormal behaviors.

3. Critical Period Mechanisms

Critical periods have been demonstrated in a variety of contexts [2]. Critical or sensitive periods exist for complex phenomena such as filial imprinting [53], acquisition of courtship song in birds [54, 55], sound localization [56], and fear extinction [57–59]. They also exist for primary sensory modalities and such as tonotopic map refinement in auditory cortex [60] and barrel formation [61] and tuning to whisker stimulation [62, 63] in rodent somatosensory cortex. One of the most mechanically well-characterized critical periods is for ocular dominance (OD) plasticity in the mammalian visual cortex. Here, we will focus our discussion on the OD critical period because its underlying molecular and cellular mechanisms have been extensively dissected, making it the best model system for testing our hypothesis that critical periods may be abnormal in autism.

Abnormal visual input to one eye during infancy results in permanent loss of visual acuity, amblyopia (Greek for dull vision), if not corrected during childhood. If perturbation of vision occurs in adulthood, the visual impairments are significantly milder or absent [64]. This observation in humans inspired the development of a simple laboratory paradigm to test the existence of a critical period in animal models. David Hubel and Torsten Wiesel began investigating OD plasticity in a series of Nobel Prize winning experiments in the 1960s [65, 66].
They found that the closure of one eye (monocular deprivation) of a kitten during a specific time window early in postnatal life results in an experience-dependent loss of visual acuity in the deprived eye despite no physical damage to the eye itself [67]. This is due to a competitive invasion by the nondeprived eye into cortical territory previously responsive to the deprived eye. A functional loss of responsiveness to the deprived eye and an increase of responsiveness to the open eye are followed first by pruning and then regrowth of dendritic spines on cortical pyramidal neurons [68, 69]. Further structural reorganization takes place in the form of shrinking thalamocortical projections (OD columns) serving the deprived eye and expansion of those serving the open eye [70].

The ocular dominance critical period is present in all mammals tested so far, from humans to mice, and the duration of plasticity is in direct correlation to lifespan and brain weight [71]. The identification of rodents as models of amblyopia has made possible a fine dissection of the mechanisms underlying critical period expression. In particular, by taking advantage of genetically modified mouse models, a specific inhibitory circuit has been identified that controls the mechanisms underlying critical period expression. Fine manipulation of inhibitory transmission is difficult in vivo, because enhancing inhibition silences the brain, while reducing inhibition easily induces epilepsy. With the generation of a mouse lacking only one of the two enzymes that synthesizes GABA (GAD65), researchers were able to titrate down the level of inhibition and test its role in the OD critical period [12]. Strikingly, the visual cortex of GAD65 knockout mice remains in an immature, precritical period state throughout life. At any age, functionally enhancing GABAergic transmission with benzodiazepine treatment triggers the opening of a normal-length critical period [72]. Historically, inhibitory neurotransmission was believed to develop postnatally to progressively restrict plasticity, but these key experiments proved GABA to actually be necessary for a normal OD critical period, prompting further investigation into the role of inhibition in brain plasticity.

Inhibitory interneurons account for nearly 20% of cortical neurons and exhibit heterogeneous morphological and physiological characteristics [73]. Included in this large variety of inhibitory interneurons is a specific subset of GABAergic neurons that expresses the calcium-binding protein parvalbumin. Fast-spiking parvalbumin-positive basket cells (PV-cells) regulate critical period timing and plasticity [11, 74]. PV-cells develop with a late postnatal time course in anticipation of critical period onset across brain regions [75, 76]. In the visual cortex, PV-cells mature in an experience-dependent manner, and dark-rearing delays their maturation as well as critical period expression [77, 78]. On the other hand, overexpression of brain-derived neurotrophic factor (BDNF) promotes the maturation of PV-cells and speeds up the onset of the OD critical period [77, 79]. Moreover, Di Cristo et al. [80] have shown that premature cortical removal of polysialic acid (PSA), a carbohydrate polymer presented by the neural cell adhesion molecule (NCAM), results in a precocious maturation of perisomatic innervation of pyramidal cells by PV-cells, enhanced inhibitory synaptic transmission, and an earlier onset of OD plasticity. Recent results indicate that PV-cell maturation is surprisingly regulated by the Otx2 homeoprotein, an essential morphogen for embryonic head formation [78]. Otx2 is stimulated by visual experience to pass from the retina to visual cortex and selectively into PV-cells, thereby promoting their maturation and consequently activating OD critical period onset in the visual cortex.

PV-cells receive direct thalamic input and also connect to each other in large networks across brain regions by chemical synapses and gap junctions [81, 82]. Moreover, PV-cells form numerous synapses onto the somata of pyramidal cells, which in turn enrich these sites with GABA_A receptors containing the α1-subunit [11, 70, 74, 78, 83]. This makes PV-cells perfectly situated to detect changes in sensory input, to regulate the spiking of excitatory pyramidal cells, and to synchronize brain regions [84–86]. Manipulations that disrupt this specific circuit will disrupt the OD critical period [87]. Recent studies have made much progress regarding the origin and fate determination of cortical interneurons [88]. In particular, progenitors of PV-cells derive from the medial ganglionic eminence with a relatively late birth date, and their differentiation and migration into specific cortical layers can be regulated by homeoproteins like Lhx6 [88, 89], or excitatory projection neurons [90]. Although the closure of the OD critical period is tightly regulated, transplanting immature GABAergic cells into the visual cortex can realow OD plasticity later in life [91]. This second sensitive period only emerges once the newly transplanted GABAergic cells reach a critical maturation stage of connectivity. This further supports a key role of inhibition in the timing of experience-dependent circuit refinement.

Once the critical period is initiated, plasticity is only possible for a set length of time, and then the critical period closes [92]. Several functional and structural brakes on plasticity have been identified in recent years [93]. Disruption of these brakes in the adult brain allows critical periods to reopen and neuronal circuits to be reshaped. In the case of OD plasticity, this means that monocular deprivation in adulthood would induce a shift in responsiveness to the nondeprived eye and cause a loss of acuity in the deprived hemisphere. Interestingly these brakes share a common theme of regulating E/I balance, and particularly the GABAergic system. Locally reducing inhibition in adulthood restores plasticity in visual cortical circuits [94, 95]. Treatment with the antidepressant drug fluoxetine also reopens plasticity, potentially by altering inhibitory neurotransmission and increasing BDNF levels [96, 97]. Finally, knocking out lynx1, an endogenous prototoxin that promotes desensitization of the nicotinic acetylcholine receptor (nAChR), extends the critical period into adulthood [98]. Lynx1 likely modulates E/I balance because treatment with diazepam in lynx1 knockout mice abolishes adult plasticity by restoring this balance to normal adult levels.

Structural factors also restrict remodeling of circuits with the closure of critical periods. For example, PV-cells become increasingly enwrapped in perineuronal nets (PNN) of extracellular matrix with the progression of the critical period, and enzymatic removal of these nets or disruption of
their formation restores plasticity in adulthood [78, 99, 100]. In addition, the maturation of myelination throughout the layers of the visual cortex, as measured by myelin basic protein (MBP) levels, increases as the critical period closes [101]. Myelin signaling through Nogo receptors (NgRs) limits plasticity in adulthood, and genetic or pharmacological disruption of this receptor allows persistent OD plasticity later in life [101, 102].

In addition to reopening plasticity, disruption of these brakes also may allow recovery from early deprivation-induced loss of function, like amblyopia. In order to test this, animals are subjected to long-term monocular deprivation spanning the critical period. This results in permanent amblyopia, even if the deprived eye is reopened in adulthood and allowed to receive visual input. Significantly, some of the manipulations described above allow recovery of acuity, including enzymatic degradation of PNNs [103], disruption of NgR signaling [102], administration of fluoxetine [96], and enhanced cholinergic signaling by lynx1 knockdown or treatment with acetylcholinesterase inhibitors [98]. Treatment with drugs like fluoxetine and acetylcholinesterase inhibitors offers particularly promising therapeutic potential because they are already FDA-approved for human use. As the mechanisms behind the closure of critical periods are explored, more light will be shed on potential interventions that could reopen plasticity or reset abnormal critical periods by restoring the brain to a more juvenile-like state.

While evidence that very distinct critical periods may share a common role for PV-cells and PNNs is promising, the causal relationship remains unclear. In support of inhibitory disruption, studies on autistic patients demonstrate broad alterations in the GABAergic system. The levels of GABA measured in the plasma of autistic children may be elevated [122, 123] while the enzymes that synthesize GABA (GAD65 and GAD67) are known about the importance of inhibitory transmission to critical period regulation, it is quite interesting to consider the evidence that inhibition, or E/I balance in general, is disrupted in neurodevelopmental disorders such as autism. A summary of the key evidence supporting the notion of E/I imbalance in autism is presented below.

4. GABAergic Inhibition in Autistic Patients

Autism is heritable, as evidenced by a very high concordance rate between monozygotic twins and a significant sibling risk [107]. However, it is difficult to sift through the many autism genetics studies, and many reports must be interpreted with caution. In any case, it is interesting that many genes that have been either directly or indirectly implicated are involved in establishing or maintaining E/I balance throughout life (see Table 1). An emerging trend from autism genetic studies is the disruption of synaptic components, like cell-adhesion molecules (CAMs) [108]. CAMs play a crucial role in synaptic development by initiating contact between pre- and postsynaptic cells, maintaining adhesion, and anchoring scaffolding proteins that assemble the essential components of a synapse. CAMs can determine the identity and function of synapses, thereby having a direct influence on E/I balance. This is exemplified by the pre- and postsynaptic pair of neurexins and neuroligins, for which different isoforms are expressed at inhibitory or excitatory synapses. Neuroligin-3 is a postsynaptic transmembrane molecule that is localized at both excitatory and inhibitory synapses, where it binds with presynaptic neuroligins [109]. A point mutation (R451C) that replaces an arginine with a cysteine in the extracellular portion of neuroligin-3 was identified in two brothers, one with severe autism and the other with Asperger syndrome [110]. In addition, a mutation in neuroligin-4 has been discovered in another set of autistic brothers [110]. Shank-3, the causal gene for 22q13 deletion syndrome, has also been found to be disrupted in autism [108, 111–113]. Other CAMs or associated molecules have been implicated in autism as well, including neurexin-1, cadherin, protocadherin, contactins, and CASK [108].

Though there is clearly a genetic basis to nonsyndromic autism, there is no single gene or family of genes that is exclusively implicated. Rather, it is likely the inheritance of several risk factors, perhaps in combination with an environmental or epigenetic trigger, that ultimately cause autism. This would fit with the E/I imbalance theory, where the presence of one mutation that increases excitation may not alone be sufficient to disrupt the balance whereas coinheritance of this mutation with another that decreases inhibition would be enough to prevent homeostatic correction and result in a dramatic E/I imbalance [42]. There is substantial evidence of altered inhibition in autistic patients, suggesting a lack of homeostatic correction and a resulting E/I imbalance.

In support of inhibitory disruption, studies on autistic patients demonstrate broad alterations in the GABAergic system. The levels of GABA measured in the plasma of autistic children may be elevated [122, 123] while the enzymes that synthesize GABA (GAD65 and GAD67) are
Table 1: Excitatory/inhibitory balance-related genes implicated in autism.

| Gene/chromosomal region | Type of disruption | Function | Reference |
|-------------------------|-------------------|----------|-----------|
| 15q11–13 (GABRB, GABRA5, GABRG3) | Chromosomal abnormalities | GABA\(_{\alpha3}\), GABA\(_{\alpha5}\), GABA\(_{\gamma3}\) subunits | [15, 114] |
| D2S2188 (2q) (DLX1, DLX2, GAD65) | High LOD score | Regulation of telencephalic GABAergic neuron development; GABA synthesizing enzyme | [19, 115] |
| D7S477 (7q) (DLX5, DLX6) | High LOD score | Regulation of forebrain GABAergic neuron development | [19, 115] |
| RELN | SNPs, CNVs, rare variants | Neuronal migration, lamination, minicolumn formation, neurotransmission regulation and synaptic plasticity | [15, 116] |
| Neurexin-1 | Chromosomal abnormalities, CNVs | Presynaptic cell adhesion molecule | [108, 110] |
| Shank-3 | Deletions, rare mutations, chromosomal abnormalities. | Postsynaptic scaffolding protein | [108, 111–113] |

significantly reduced (~50%) in postmortem autistic parietal cortex and cerebellum [124, 125]. The relevance of GABA levels measured in the plasma to the actual levels in the brain is unfortunately unclear. Multiple studies have also found both GABA\(_{A}\) and GABA\(_{B}\) receptor disruption in autistic brains [126–129]. Altered modulation of GABA\(_{A}\) receptors in the presence of GABA was suggested by a study that detected reduced radioactively labeled benzodiazepine binding to hippocampal GABA\(_{A}\) receptors [130]. On a more structural level, autistic neocortical minicolumn number was increased and width decreased, indicating abnormal cortical organization regulated by inhibitory circuitry [131, 132]. In addition, cortical projection neurons exhibited increased dendritic spine densities, providing structural evidence for changes in connectivity in autism [133]. These combined data support the notion of changes in E/I balance at the level of cells, synapses, and circuits in autism.

4.1. Syndromic Autism. Perhaps the most striking indication of E/I imbalance is that approximately 30% of autistic patients also have epilepsy [134]. This predisposition to seizures suggests an increase in excitation and/or a decrease in inhibition, ultimately resulting in uncontrollable synchronous neuronal firing. Interestingly, Rett, Fragile X, and Angelman syndrome are not only associated with autism, but they all share a predisposition to epilepsy and other evidence of E/I imbalance. Each of these disorders has an identified and well-characterized genetic disruption (MeCP2, Fmr1, and 15q11-13/Ube3a, resp.). For each of these diseases, a certain percentage of the patients also fulfill the diagnostic requirements for autism. These are all disorders where a complex pattern of gene expression is disrupted, particularly affecting genes that regulate experience-dependent plasticity. Although these patients also exhibit other confounding symptoms not specific to autism, the advantage of studying these disorders as models of autism is the clear etiology and the relative homogeneity of patients in contrast to those with nonsyndromic autism.

4.1.1. Rett Syndrome. Rett syndrome is a rare X-linked disorder that affects 1 in 10,000 girls. Typically a girl with Rett Syndrome will develop normally until 6 to 18 months of age, and then undergo developmental regression, including hand wringing or clapping, loss of motor coordination, breathing abnormalities, seizures, shortened lifespan, and autism. Most cases are caused by de novo mutations in the gene Methyl Cpg binding protein 2 (MeCP2) [135]. MeCP2 binds to methylated DNA and represses or activates gene transcription. Thus, the disruption of MeCP2 leads to aberrant expression of a variety of genes. Studies in human Rett syndrome patients have identified clear signs of altered E/I balance, including abnormal cortical excitation in the form of altered somatosensory evoked potentials, abnormal EEG recordings [136], decreased cortical minicolumn size [132], reduced dendritic spine number [137, 138], and altered development of glutamate and GABA receptors in the basal ganglia [139]. Interestingly, GABRB3 is a target of MeCP2, which could be a potential direct mechanism for abnormal GABA\(_{A}\) receptor number found in Rett Syndrome [140]. MeCP2 also regulates the expression of BDNF in an activity-dependent manner [141–143]. The expression of BDNF promotes GABAergic maturation, and manipulation of BDNF levels alters the timing of the ocular dominance critical period [77].
Experiments in a mouse model of Rett syndrome identified therapeutic potential in an FDA-approved drug, Insulin-like growth factor 1 (IGF-1) [144]. Systemic IGF-1 treatment of juvenile mice prevents many of the Rett syndrome symptoms, including shortened lifespan, locomotion and respiration, decreased brain weight, decreased cortical spine density, and abnormal ocular dominance plasticity. IGF-1 is known to stimulate synaptic maturation, function, and plasticity, though its exact mechanism of action is still unknown. IGF-1 is now in phase I and II clinical trials at Children’s Hospital Boston to treat children with Rett syndrome (http://www.clinicaltrials.gov/, NCT01253317).

4.1.2. Fragile X Syndrome. Fragile X syndrome (FXS) is the most frequent cause of male mental retardation and the most common identified cause of autism, accounting for 2–5% of all known cases. FXS patients exhibit cognitive impairment, hyperactivity, anxiety, social deficits, repetitive motor behaviors, hypersensitivity to sensory stimuli, motor problems, and an increased incidence of epilepsy [19]. In addition, approximately 25% of FXS patients also have autism [15]. This disorder is most commonly caused by a trinucleotide repeat expansion in the promoter of the Fragile X mental retardation 1 (Fmr1) gene on the X chromosome, resulting in transcriptional silencing of the gene and reduction of Fragile X mental retardation protein (FMRP) [145]. FMRP is an mRNA binding protein that regulates the translation and transport of many synaptic proteins that are important for activity-dependent plasticity. Therefore, Fmr1 mutations disrupt normal activity-dependent regulation of many different proteins. Postmortem analysis of FXS brains has revealed an increased number of long, thin dendritic spines on excitatory cortical neurons, a phenotype suggestive of immature synapses [146, 147].

The predominant mechanistic theory for FXS is the “metabotropic glutamate receptor (mGluR) theory” [148]. According to this model, reduction of FMRP releases negative regulation of mGlur-dependent long-term depression (LTD), and ultimately causes exaggerated LTD at excitatory synapses onto other excitatory neurons. According to this hypothesis, a net loss of synapses would occur, potentially accounting for many of the symptoms of FXS, like developmental delay, cognitive impairment, and the preponderance of immature spines on excitatory neurons. In support of this theory, the FXS phenotype can be rescued by pharmacological treatment of mGluR inhibitors in drosophila, zebrafish, and mice, and by genetic manipulation of mGluR expression in mice. These animal model studies have paved the way for human clinical trials that are now in progress to test the efficacy of drugs that target mGluR5 function. These include several mGluR5 antagonists, such as AFQ056 from Novartis (http://www.clinicaltrials.gov/) [149], RO4917523 from Hoffmann-La Roche (http://www.clinicaltrials.gov/), and STX107 from Seaside Therapeutics (http://www.seaside-therapeutics.com/). Arbaclofen, a GABA\_A agonist that indirectly inhibits mGluR5 signaling, is also being tested (http://www.sea-sidetherapeutics.com/).

Interestingly, mGluR5 is highly expressed at excitatory presynaptic terminals onto fast-spiking inhibitory neurons and regulates long-term potentiation (LTP) at this connection [150]. Alteration of mGluR5 activity, for example in FXS, could dramatically alter the dynamics of plasticity at this type of synapse, and ultimately affect the overall inhibitory output of fast-spiking cells. In fact, in vitro recordings from an FXS mouse model have shown a large reduction of excitatory drive onto fast-spiking cells [151]. The role of mGluR5-dependent LTP at this type of connection should be investigated in FXS to fully assess the impact of mGluR5 dysregulation on E/I balance. In relation to this, evidence of GABA\_A\_Rs disruption has also been documented in FXS, expanding the scope of E/I imbalance in syndromic autism [152]. GABA\_A\_Rs are known to affect learning, memory, anxiety, depression, and epilepsy, all of which are disrupted in FXS.

4.1.3. Angelman Syndrome. Angelman syndrome (AS) is characterized by normal development during the first year of life followed by progressive mental retardation, motor dysfunction, speech impairment, and a high rate of autism [153]. AS is caused by maternal deletion of chromosome 15q11–13 and by more specific deletions of a gene found in this region, called E3 ubiquitin ligase (Ube3a). The transcription of Ube3a is normally regulated by synaptic activity and ultimately regulates excitatory synapse development. Ube3a regulates AMPA receptor internalization by controlling the degradation of Arc, an activity-regulated cytoskeleton-associated protein [154]. In the absence of Ube3a, Arc expression increases, more AMPA receptors are internalized, and excitatory synaptic transmission is reduced. Ube3a appears to be a key causal gene in AS, but the chromosomal segment 15q11–13 also contains other genes that likely contribute to the AS phenotype—most notably the GABA\_A receptor gene cluster.

Individuals with 15q11–13 deletions usually have more severe epilepsy than those with more specific Ube3a mutations that spare the GABA\_A receptor gene cluster [155]. The \( \beta^3-\alpha^5-\gamma^3 \) GABA\_A subunit gene cluster encodes three of the ionotropic GABA receptor subunits. As would be expected, postmortem AS cortex shows abnormal subunit composition of these receptors, favoring other subunits that are not in this gene cluster (e.g., \( \beta^2 \) and \( \alpha^1 \)). When these receptors were injected into xenopus oocytes, GABAergic transmission was altered, with a particular disruption of receptor pharmacology [156]. These results suggest that synaptic cortical GABAergic inhibition is intact or even augmented, but extrasynaptic inhibition is impaired. The authors suggest that this could account for the cognitive, behavioral, and epileptic symptoms of AS.

5. GABAergic Inhibition in Animal Models of Autism

For many human diseases, the generation and characterization of animal models is an essential bridge between understanding the molecular features of the disease and
the development of therapeutics. Unfortunately, the generation of mouse models of autism has been quite difficult and controversial. The reasons for this become apparent when considering the three ideal characteristics of an effective mouse model for neuropsychiatric diseases—face, construct, and predictive validity (similarity to human symptoms, cause of human disease, and response to treatment, resp.) [157, 158]. In the case of autism, face validity requires rigorous behavioral tests to examine socialization, communication, and repetitive behavior, which are rather difficult, though possible, to do in mice. In addition, the variability of human symptoms combined with the inherent variability of mouse behavior results in the need to test many mice with multiple different tasks to evaluate these three categories of behavior. Construct validity is also difficult because as discussed previously, the cause of the majority of autism cases is unknown. Finally, in the case of autism, no single treatment has been shown to have consistent positive results, thereby also making predictive validity complicated [18].

Over the years, mouse models of autism have been generated based on rare mutations identified in autism patients, environmental insults associated with autism, or mutations known to cause diseases that are comorbid with autism (reverse genetic approach). Existing mouse strains have also been screened for behaviors relevant to autism (forward genetic approach). In this section, several different mouse models of autism are reviewed, with their common disruption of E/I balance receiving special attention.

5.1. Cell-Adhesion Molecules. As mentioned previously, disruption of cell-adhesion molecules is a common theme emerging from autism genetic studies [108], including a point mutation in neuroligin-3 (R451C) [110], and mutations in Shank-3 [111–113]. Studies of the R451C mutation in neuroligin-3 in cell culture have shown that 90% of the mutant protein is retained in the endoplasmic reticulum [159, 160]. The 10% of the protein that is transported to the cell surface exhibits reduced binding with its presynaptic partner, the neurexin molecule [159]. Interestingly, when this mutation is introduced in mice by homologous recombination, mice show upregulation of inhibitory markers per synapse, including vesicular GABA transporter (VGAT) and the postsynaptic scaffolding protein gephyrin [161]. However, the ratio of inhibitory to excitatory synapses is preserved. There is also a functional increase in inhibitory transmission in the somatosensory cortex evidenced by increased frequency of mIPSCs, increased amplitude of eIPSCs, and increased IPSC amplitude in response to GABA application. Mutant mice show some behaviors relevant to autism, including altered socialization and enhanced spatial learning (but also see [162]). None of these same molecular, physiological, and behavioral phenotypes were found in neuroligin-3 knockout mice, suggesting that this particular mutation results in a gain-of-function, though the mechanism is still under investigation. A very recent study also found that introducing the R451C mutation in the motor neuron of *Aplysia* blocks intermediate-term and long-term facilitation that are necessary for memory storage, possibly having implications for social memory [163]. In addition, mice lacking neuroligin-4 demonstrate deficits in reciprocal social interaction and reduced ultrasonic vocalization, providing further evidence that mutant *neuroligin* mouse models may be very useful to study autism [164].

Another recent autism mouse model based on cell-adhesion molecule disruption was generated by mutating the Shank-3 gene [165]. These mice demonstrate anxious behavior, decreased social interaction, and impaired social novelty recognition. Most strikingly, they compulsively self-groom to the point of causing skin lesions. Compulsive grooming is generally considered to be the result of a corticostratial abnormality. Hence, Peca et al. investigated the corticostratial circuitry of these mice using a joint structure-function approach. They focused on excitatory synapses onto inhibitory medium spiny neurons (MSNs) of the striatum, because Shank-3 is located in the excitatory postsynaptic density. They found altered postsynaptic density composition, abnormal morphology of MSNs, and reduced corticostratial neurotransmission due to postsynaptic changes. In summary, Shank-3 disruption results in striking autism-like behaviors and an E/I imbalance in the striatum. Based on this phenotype, the causal role of Shank-3 in 22q13 syndrome [111, 166, 167], and an emerging association of Shank-3 with autism [112, 113], this mouse model should be a valuable tool with which to further dissect E/I imbalance and circuit disruption in autism.

5.2. Prenatal Valproic Acid Insult. Other mouse models of autism incorporate the polygenetic complexity of the disease by mimicking an embryonic insult that has been linked to autism in humans. For example, human embryonic exposure to valproic acid (VPA) during a strict time window of 20–24 days post-conception is linked to a seven-fold increased likelihood of developing autism [168–171]. VPA is an anticonvulsant and mood stabilizer used to treat epilepsy and bipolar disorder, and is also a pharmacological histone deacetylase (HDAC) inhibitor. As such, VPA interferes with normal deacetylation of chromatin and causes aberrant expression of many genes, possibly including *Homeobox (Hox)* genes and *Wingless-Int (Wnt)* [172]. Rodent VPA models of autism have been generated by treating a pregnant female with a single dose of VPA at a time during embryonic development that is equivalent to the human susceptibility time window. Multiple studies from different groups have shown that the resulting offspring exhibit developmental, behavioral, molecular, and anatomical changes comparable to human autism symptoms [173]. Interestingly, a dramatic E/I imbalance is manifest in VPA-treated rats, with NMDAR-mediated synaptics currents, NR2A and NR2B subunit number, and postsynaptic LTP all showing enhancement in the somatosensory cortex [174]. Further, the medial prefrontal cortex, somatosensory cortex, and amygdala demonstrate local hyperconnectivity, hyperreactivity, and hyperplasticity in rats treated embryonically with VPA [175, 176].

5.3. BTBR T + tf/Inbred Mouse Strain. One way to identify new mouse models of autism is to screen existing strains of
mice of varying genetic backgrounds for behaviors relevant to autism. This forward genetic strategy requires a high-throughput, reliable behavioral battery that can evaluate mice on a variety of behavioral tests, from general health to cognitive abilities. Using this strategy, Mc Farlane [177] an inbred strain of mice was identified, BTBR T + tf/J (BTBR) that exhibits all three categories of autistic behaviors in a very specific manner. BTBR mice show reduced social approach, reciprocation, and play. They also exhibit communication deficits as evidenced by impaired transmission of food preference [177], and an unusual pattern of ultrasonic vocalizations [178]. Finally, BTBR mice are afflicted with extreme repetitive behavior in the form of high levels of self-grooming throughout life [177]. These autism-like behaviors are specific due to absence of anxiety or motor impairments that could complicate the interpretation of the affected behaviors. Interestingly, the high grooming behavior can be corrected by treatment with MPEP [179], an mGluR5 antagonist whereas the abnormal socialization can be corrected by treatment with fluoxetine [180], showing good predictive validity for this model. MPEP is effective in treating autism-related symptoms in the Fmr1 mouse model of Fragile X syndrome [181–184], and fluoxetine is under evaluation to treat repetitive behavior and anxiety in autistic patients and is currently used to treat depression [180]. Interestingly, fluoxetine treatment in adult mice has been shown to reopen ocular dominance plasticity [96]. This effect may be mediated by inhibitory systems, as diazepam infusion into the cortex prevents this effect. Future studies should investigate GABAergic changes in the BTBR mouse.

5.4. Rett Syndrome. Deletion of part or all of MeCP2’s third exon results in mice that strikingly recapitulate many Rett syndrome symptoms [185–187]. These mice develop progressive symptoms, including clasping of the front paws, anxiety, tremors, respiratory problems, seizures, hypoactivity, and a shortened lifespan. They also demonstrate autistic behaviors, including altered ultrasonic vocalizations [188]. One mutation present in Rett syndrome patients that results in truncation of the MeCP2 protein causes disrupted social behavior [189, 190], altered home cage activity [189], and impaired learning and memory in mice [191]. A general feature of these Rett syndrome mouse models is disrupted excitation, shown by reduced dendritic spine number [137, 138], reduced spontaneous activity due to reduced mEPSC amplitude [192], and minor LTP deficits early in life due to reduced excitatory synaptic connectivity that progressively worsens with age [191, 193].

Deficits in inhibitory transmission have also been noted in Rett syndrome mouse models. For example, GABAergic synaptic transmission in the ventrolateral medulla is depressed at P7 in MeCP2 knockout mice, a phenotype that likely stems from both reduced presynaptic GABA release (i.e., reduced VGAT) and reduced GABA_A receptor subunit levels [194]. Based on the observation that wild-type GABAergic neurons express 50% more MeCP2 than wildtype non-GABAergic cells, a conditional mutant mouse was generated where MeCP2 was exclusively disrupted in GABAergic cells using a VGAT-Cre mouse line [195]. These mice developed nearly all of the same symptoms as global MeCP2 knockout mice, including limb clasping, self-injury from excessive grooming, motor deficiencies, increased pre-pulse inhibition, altered socialization, and decreased lifespan. GABAergic neurons exhibited reduced inhibitory quantal size, reduced GAD65 and GAD67 levels, and reduced GABA immunoreactivity. In addition, specific knockout of MeCP2 in forebrain GABAergic neurons with the use of a Dlx 5/6 promoter also recapitated many of the symptoms seen in global MeCP2 knockout mice [195]. This study suggests that disruption of MeCP2 exclusively in inhibitory neurons is sufficient to cause Rett syndrome in mice.

Reactivation of endogenous MeCP2, BDNF overexpression, and pharmacological and environmental interventions can rescue some aspects of Rett-like pathology [196]. This suggests the possibility of rescuing Rett syndrome symptoms by directly acting on mechanisms which normally control plasticity in developing cortical circuits.

5.5. Fragile X Syndrome. The Fmr1 knockout mouse generated by Bakker et al. [197], recapitulates many FXS phenotypes. These include abnormal socialization, learning and cognitive deficits, susceptibility to audiogenic seizures, and long, thick dendritic spines. Changes in glutamatergic and GABAergic systems have been reported in both mouse and fly models of FXS (see [198] for review). In particular, the cortex of mouse models of FXS show a decrease in LTP and an increase in glutamatergic cells, but a decrease in GAD and GABA_A subunit mRNA, decreased GABAergic cell number, and decreased excitatory drive onto inhibitory neurons. In the hippocampus, there is increased mGluR-dependent LTD, increased epileptiform discharges, as well as decreased GABA_A subunits and decreased tonic inhibition. Interestingly, both brain regions show elevated GAD protein levels despite decreased mRNA levels. Although results are variable due to differences in age, brain region, and method, the underlying theme appears to be an increased excitatory/inhibitory ratio.

5.6. Angelman Syndrome. Angelman syndrome has been successfully modeled in mice by inactivation of the maternal copy of Ube3a [199, 200]. This manipulation results in learning and hippocampal LTP deficits [199, 201], as well as deficient experience-dependent maturation of excitatory circuits [202]. Knocking out GABRB3, which is found on the 15q11-13 chromosomal segment, also produces a mouse model that seems very relevant to AS [203]. This mouse has problems with coordination and learning, is hyperactive, and has seizures and abnormal EEG patterns [203, 204]. In addition, the pharmacological function of GABA_A receptors is altered, as binding of benzodiazepines is reduced [205].

6. Critical Period Disruption in Animal Models of Autism

Critical period plasticity has been reported to be altered in at least three animal models of syndromic autism
Yashoria et al. [202]. Examined OD plasticity in a maternal Ube3a knockout mouse model of Angelman syndrome. They recorded chronic visual evoked potentials (VEP) in response to low spatial frequency stimuli in order to evaluate the strength of input from each eye before and after monocular deprivation (MD) during the canonical critical period. Interestingly, these mutant mice did not exhibit any shift in favor of the open nondeprived eye. This was due to a lack of depression of the deprived contralateral eye response. *In vitro* analysis revealed that cortical synapses were still immature and unable to incorporate changes in sensory experience. Unfortunately they did not test before or after the normal critical period to see if the onset was accelerated or delayed. Similarly, Sato and Stryker [206] studied OD plasticity in Ube3a-deficient mice using optical imaging of intrinsic signals to evaluate the strength of input from each eye. Consistent with the Yashio et al. study, they found that brief MD did not elicit plasticity in mutant mice during the normal critical period. However, when mice were deprived for a longer period (14 instead of 4 days), some degree of OD plasticity was revealed. Therefore, there is some capacity for plasticity during a restricted time window, but the strength is diminished.

Dölen et al. [207] tested OD plasticity in an Fmr1 knockout mouse model of Fragile X syndrome. They recorded chronic VEPs before and after brief (3-day) MD during the canonical critical period. Knockout mice showed significant potentiation of the ipsilateral open eye response but no depression of contralateral deprived eye response as is seen in wildtype mice. The potentiation of the open eye is usually only seen after longer periods of MD, secondary to the depression of the closed eye. Therefore, the knockout mice do show an OD shift during the critical period, but the nature of this shift is unusual. Furthermore, visual acuity before and after MD was not measured, so it is unknown if the deprived eye ever became amblyopic and if critical period plasticity really took place. In addition excitatory thalamo-cortical synapses in somatosensory cortex during the perinatal critical period in Fmr1 knockout mice. FMRI ablation resulted in dysregulation of glutamatergic signaling maturation. The fraction of silent synapses persisting to later developmental times was increased; there was a temporal delay in the window for synaptic plasticity, while other forms of developmental plasticity were not altered in Fmr1 knockout mice. indicating that FMRI is required for the normal developmental progression of synaptic maturation impacting the timing of the critical period for layer IV synaptic plasticity [208].

Tropea et al. [144] tested OD plasticity in adult MeCP2 heterozygous female mice that are considered an accurate model of Rett syndrome despite having less severe symptoms than MeCP2 mutant male mice. Using optical imaging of intrinsic signals, they found adult OD plasticity after 4-day MD in mutant but not wildtype mice. Plasticity was not evaluated during the normal critical period or at any other age, so it is unknown if the critical period is delayed or extended in the absence of MeCP2. Interestingly, treatment with IGF-1 peptide abolishes this aberrant plasticity, and also alleviates other symptoms of Rett syndrome in these mice.

Together these results show that critical period plasticity is abnormal in these mouse models of autism; however, the way in which critical periods are altered appears to differ depending on the particular etiology of autism. This would make sense in light of the heterogeneity that is so characteristic of autism. Therefore it is imperative to thoroughly test all aspects of critical periods to see if they are accelerated, delayed, extended, weaker, stronger, and so on (as portrayed in Figure 1). Unfortunately all of the above studies have only compared the ratio of responses between the two eyes and have not looked at the functional readout of acuity. In the future, we hope several lines of autism mouse models will be systematically analyzed, complete with an evaluation of normal visual system functional development before any sensory manipulation is performed. A detailed examination of single-cell excitability and visual spatial acuity will reveal whether the model’s visual system suffers from perturbed sensory processing, which is indicative of abnormal circuit refinement in visual cortex during development. After the baseline visual function is determined, then plasticity can be tested by short- or long-term monocular deprivation performed at various ages between eye opening and adulthood. Given the possible common disruption of PV-circuits across brain regions [58, 59] and the importance of the GABAergic system to critical period regulation [70], a multilevel analysis of PV-cell maturation should also be performed. The recent identification of new pharmacological and environmental strategies to recreate the highly plastic state of GABAergic circuits possessed by juvenile animals represents a promising therapeutic avenue for the restoration of normal function in affected neuronal circuits [93].

Finally, in addition to ocular dominance, testing other critical periods in somatosensory and auditory cortices would reveal whether any defects in critical periods in the visual system are representative of a more global phenotype.

### 7. Conclusion and Thoughts for the Future

The functional significance of critical periods is unclear, but the careful regulation of their timing indicates that their precise expression is crucial for normal development. There
is, perhaps, a tradeoff between adaptability and stability. The young brain must dynamically adapt to its environment in order to set up its circuits in the most efficient manner while the adult brain favors reliability instead.

The variable nature of E/I imbalance and altered plasticity in autism animal models suggests that the disruption of critical periods in autism is likely heterogeneous, in some cases resulting in excessive plasticity and in others, insufficient plasticity. This could be due to disruption of the mechanisms governing either the onset or closing of critical periods Figure 1, and both could be detrimental to function. A brain that is too plastic at the wrong times could result in noisy and unstable processing. On the other hand, a brain that lacks plasticity early in life might remain hyper- or hypoconnected and unresponsive to environmental changes early in life. A situation could also arise where plasticity is at an optimal level in some systems and an aberrant level in other systems, which could be the case in Asperger and/or Savant syndrome.

Autism is diagnosed exclusively by cognitive behavioral symptoms, but there are likely underlying problems arising at lower-level stages of processing. By first understanding the development of primary senses in autism, a cumulative chain reaction of abnormalities could be prevented early and save consequent behavior. In the long run, a collaborative multilevel analysis of different brain regions over development and in different animal models of autism is of paramount importance. Hypothesis-driven efforts may then have a wider implication for the diagnosis and treatment of neurodevelopmental disorders in general. We are now in the position to adopt a mouse model to human multilevel analysis approach to test well-defined, mechanistic hypothesis and to discover new therapeutic interventions to restore normal cortical function.

References

[1] L. C. Katz and C. J. Shatz, “Synaptic activity and the construction of cortical circuits,” Science, vol. 274, no. 5290, pp. 1133–1138, 1996.
[2] T. K. Hensch, “Critical period regulation,” Annual Review of Neuroscience, vol. 27, pp. 549–579, 2004.
[3] H. F. Harlow, R. O. Dodsworth, and M. K. Harlow, “Total social isolation in monkeys,” Proceedings of the National Academy of Sciences of the United States of America, vol. 54, no. 1, pp. 90–97, 1965.
[4] C. A. Nelson, C. H. Zeanah, N. A. Fox, P. J. Marshall, A. T. Smyke, and D. Guthrie, “Cognitive recovery in socially deprived young children: the Bucharest early intervention project,” Science, vol. 318, no. 5858, pp. 1937–1940, 2007.
[5] M. V. Popescu and D. B. Polley, “Monaural deprivation disrupts development of binaural selectivity in auditory midbrain and cortex,” Neuron, vol. 65, no. 5, pp. 718–731, 2010.
[6] R. V. Harrison, K. A. Gordon, and R. J. Mount, “Is there a critical period for cochlear implantation in congenitally deaf children? Analyses of hearing and speech perception performance after implantation,” Developmental Psychobiology, vol. 46, no. 3, pp. 252–261, 2005.
[7] M. A. Svirsy, S. W. Teoh, and H. Neuburger, “Development of language and speech perception in congenitally profoundly deaf children as a function of age at cochlear implantation,” Audiology and Neuro-Otology, vol. 9, no. 4, pp. 224–233, 2004.
[8] M. S. Banks, R. N. Aslin, and R. D. Letson, “Sensitive period for the development of human binocular vision,” Science, vol. 190, no. 4215, pp. 675–677, 1975.
[9] D. E. Mitchell and S. Mackinnon, “The present and potential impact of research on animal models for clinical treatment of stimulus deprivation amblyopia,” Clinical and Experimental Optometry, vol. 85, no. 1, pp. 5–18, 2002.
[10] M. Fagiolini, H. Katagiri, H. Miyamoto et al., “Separable features of visual cortical plasticity revealed by N-methyl-D-aspartate receptor 2A signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2854–2859, 2003.
[11] M. Fagiolini, J. M. Fritschi, K. Löw, M. Möhler, U. Rudolph, and T. K. Hensch, “Specific GABAergic circuits for visual cortical plasticity,” Science, vol. 303, no. 5664, pp. 1681–1683, 2004.
[12] T. K. Hensch, M. Fagiolini, N. Mataga, M. P. Stryker, S. Baekkeskov, and S. E. Kash, “Local GABA circuit control of experience-dependent plasticity in developing visual cortex,” Science, vol. 282, no. 5393, pp. 1504–1508, 1998.
[13] American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, APA, Washington, DC, USA, 4th edition, 1994.
[14] E. I. Marco, L. B. N. Hinkley, S. S. Hill, and S. S. Nagarajan, “Sensory processing in autism: a review of neurophysiologic findings,” Pediatric Research, vol. 69, no. 5, pp. 48R–54R, 2011.
[15] B. S. Abrahams and D. H. Geschwind, “Advances in autism genetics: on the threshold of a new neurobiology,” Nature Reviews Genetics, vol. 9, no. 5, pp. 341–355, 2008.
[16] D. H. Geschwind, “Autism: many genes, common pathways?” Cell, vol. 135, no. 3, pp. 391–395, 2008.
[17] Z. Warren, M. L. McPheeters, N. Sathe, J. H. Foss-Feig, A. Glasser, and J. Veenstra-VanderWeele, “A systematic review of early intensive intervention for autism spectrum disorders,” Pediatrics, vol. 127, no. 5, pp. e1303–e1311, 2011.
[18] M. L. McPheeters, Z. Warren, N. Sathe et al., “A systematic review of medical treatments for children with autism spectrum disorders,” Pediatrics, vol. 127, no. 5, pp. e1312–e1321, 2011.
[19] M. K. Belmonte, E. H. Cook, G. M. Anderson et al., “Autism as a disorder of neural information processing: directions for research and targets for therapy,” Molecular Psychiatry, vol. 9, no. 7, pp. 646–663, 2004.
[20] A. Bertone, L. Mottron, P. Jelenic, and J. Faubert, “Motion perception in autism: a “complex” issue,” Journal of Cognitive Neuroscience, vol. 15, no. 2, pp. 218–225, 2003.
[21] L. Kanner, “Autistic disturbances of affective contact,” Nervous Child, vol. 2, pp. 217–250, 1943.
[22] T. Grandin, “An inside view of autism,” in High-Functioning Individuals with Autism, E. Schopler and G. B. Mesibov, Eds., pp. 105–126, Plenum Press, New York, NY, USA, 1992.
[23] T. Grandin, “Visual abilities and sensory differences in a person with autism,” Biological Psychiatry, vol. 65, no. 1, pp. 15–16, 2009.
[24] D. Williams, “The remarkable autobiography of an autistic girl,” in Nobody Nowhere, Jessica Kingsley, London, UK, 1998.
[25] O. Bogdashina, Sensory Perceptual Issues in Autism and Asperger Syndrome: Different Sensory Experiences, Different Perceptual Worlds, Jessica Kingsley, London, UK, 2003.
[59] N. Gogolla, P. Caroni, A. Lüthi, and C. Herry, “Perineuronal nets protect fear memories from erasure,” *Science*, vol. 325, no. 5945, pp. 1258–1261, 2009.

[60] E. F. Chang and M. M. Merzenich, “Environmental noise retards auditory cortical development,” *Science*, vol. 300, no. 5618, pp. 498–502, 2003.

[61] H. Van Der Loos and T. A. Woolsey, “Somatosensory cortex: structural alterations following early injury to sense organs,” *Science*, vol. 179, no. 4071, pp. 395–398, 1973.

[62] K. Fox, “A critical period for experience-dependent synaptic plasticity in rat barrel cortex,” *Journal of Neuroscience*, vol. 12, no. 5, pp. 1826–1838, 1992.

[63] E. A. Stern, M. Maravall, and K. Svoboda, “Rapid development and plasticity of layer 2/3 maps in rat barrel cortex in vivo,” *Neuron*, vol. 31, no. 2, pp. 305–315, 2001.

[64] T. L. Lewis and D. Maurer, “Effects of early pattern deprivation on visual development,” *Optometry and Vision Science*, vol. 86, no. 6, pp. 640–646, 2009.

[65] T. N. Wiesel, “Postnatal development of the visual cortex and the influence of environment,” *Nature*, vol. 299, no. 5884, pp. 583–591, 1982.

[66] D. H. Hubel and T. N. Wiesel, “Early exploration of the visual cortex,” *Neuron*, vol. 20, no. 3, pp. 401–412, 1998.

[67] T. N. Wiesel and D. H. Hubel, “Single-cell responses in striate cortex of kittens deprived of vision in one eye,” *Journal of Neurophysiology*, vol. 26, pp. 1003–1017, 1963.

[68] S. Oray, A. Majewska, and M. Sur, “Dendritic spine dynamics are regulated by monocular deprivation and extracellular matrix degradation,” *Neuron*, vol. 44, no. 6, pp. 1021–1030, 2004.

[69] N. Mataga, Y. Mizuguchi, and T. K. Hensch, “Experience-dependent pruning of dendritic spines in visual cortex by tissue plasminogen activator,” *Neuron*, vol. 44, no. 6, pp. 1031–1041, 2004.

[70] T. K. Hensch, “Critical period plasticity in local cortical circuits,” *Nature Reviews Neuroscience*, vol. 6, no. 11, pp. 877–888, 2005.

[71] N. Berardi, T. Pizzorusso, and L. Maffei, “Critical periods during sensory development,” *Current Opinion in Neurobiology*, vol. 10, no. 1, pp. 138–145, 2000.

[72] M. Fagiolini and T. K. Hensch, “Inhibitory threshold for critical-period activation in primary visual cortex,” *Nature*, vol. 404, no. 6774, pp. 183–186, 2000.

[73] H. Markram, M. Toledo-Rodriguez, Y. Wang, A. Gupta, G. Silberberg, and C. Wu, “Interneurons of the neocortical inhibitory system,” *Nature Reviews Neuroscience*, vol. 5, no. 10, pp. 793–807, 2004.

[74] H. Katagiri, M. Fagiolini, and T. K. Hensch, “Optimization of somatic inhibition at critical period onset in mouse visual cortex,” *Neuron*, vol. 53, no. 6, pp. 805–812, 2007.

[75] J. A. Del Rio, L. De Lecea, I. Ferrer, and E. Soriano, “The development of parvalbumin-immunoreactivity in the neocortex of the mouse,” *Developmental Brain Research*, vol. 81, no. 2, pp. 247–259, 1994.

[76] B. Chattopadhyay, G. Di Cristo, H. Higashiyama et al., “Experience and activity-dependent maturation of perisomatic GABAergic innervation in primary visual cortex during a postnatal critical period,” *Journal of Neuroscience*, vol. 24, no. 43, pp. 9598–9611, 2004.

[77] Z. J. Huang, A. Kirkwood, T. Pizzorusso et al., “BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex,” *Cell*, vol. 98, no. 6, pp. 739–755, 1999.

[78] S. Sugiyama, A. A. Di Nardo, S. Aizawa et al., “Experience-dependent transfer of Otx2 homeoprotein into the visual cortex activates postnatal plasticity,” *Cell*, vol. 134, no. 3, pp. 508–520, 2008.

[79] J. L. Hanover, Z. J. Huang, S. Tonegawa, and M. P. Stryker, “Brain-derived neurotrophic factor overexpression induces precocious critical period in mouse visual cortex,” *The Journal of Neuroscience*, vol. 19, no. 22, p. RC40, 1999.

[80] G. Di Cristo, B. Chattopadhyay, S. J. Kuhlman et al., “Activity-dependent PSA expression regulates inhibitory maturation and onset of critical period plasticity,” *Nature Neuroscience*, vol. 10, no. 12, pp. 1569–1577, 2007.

[81] S. I. Cruikshank, T. J. Lewis, and B. W. Connors, “Synaptic basis for intense thalamocortical activation of feedforward inhibitory cells in neocortex,” *Nature Neuroscience*, vol. 10, no. 4, pp. 462–468, 2007.

[82] M. Galarreta and S. Hestrin, “A network of fast-spiking cells in the neocortex connected by electrical synapses,” *Nature*, vol. 402, no. 6757, pp. 72–75, 1999.

[83] T. Klausberger, “GABAergic interneurons targeting dendrites of pyramidal cells in the CA1 area of the hippocampus,” *European Journal of Neuroscience*, vol. 30, no. 6, pp. 947–957, 2009.

[84] J. DeFelipe and I. Farinas, “The pyramidal neuron of the cerebral cortex: morphological and chemical characteristics of the synaptic inputs,” *Progress in Neurobiology*, vol. 39, no. 6, pp. 563–607, 1992.

[85] Y. Kawaguchi and Y. Kubota, “GABAergic cell subtypes and their synaptic connections in rat frontal cortex,” *Cerebral Cortex*, vol. 7, no. 6, pp. 476–486, 1997.

[86] P. Somogyi, G. Tamás, R. Lujan, and E. H. Buhl, “Salient features of synaptic organisation in the cerebral cortex,” *Brain Research Reviews*, vol. 26, no. 2–3, pp. 113–135, 1998.

[87] A. Sale, N. Berardi, M. Spolidoro, L. Baronielli, and L. Maffei, “GABAergic inhibition in visual cortical plasticity,” *Frontiers in Cellular Neuroscience*, vol. 4, pp. 4–10, 2010.

[88] C. P. Wonders and S. A. Anderson, “The origin and specification of cortical interneurons,” *Nature Reviews Neuroscience*, vol. 7, no. 9, pp. 687–696, 2006.

[89] S. J. B. Butt, I. Cobos, J. Golden, N. Kessaris, V. Pachnis, and S. Anderson, “Transcriptional regulation of cortical interneuron development,” *Journal of Neuroscience*, vol. 27, no. 44, pp. 11847–11850, 2007.

[90] S. Lodato, C. Rouaux, K. Quast et al., “Excitatory projection neuron subtypes control the distribution of local inhibitory interneurons in the cerebral cortex,” *Neuron*, vol. 69, no. 4, pp. 763–779, 2011.

[91] D. G. Southwell, R. C. Froemke, A. Alvarez-Buylla, M. P. Stryker, and S. P. Gandhi, “Cortical plasticity induced by inhibitory neuron transplantation,” *Science*, vol. 327, no. 5969, pp. 1145–1148, 2010.

[92] J. A. Gordon and M. P. Stryker, “Experience-dependent plasticity of binocular responses in the primary visual cortex of the mouse,” *Journal of Neuroscience*, vol. 16, no. 10, pp. 3274–3286, 1996.

[93] D. Bavelier, D. M. Levi, R. W. Li, Y. Dan, and T. K. Hensch, “Removing brakes on adult brain plasticity: from molecular to behavioral interventions,” *Journal of Neuroscience*, vol. 30, no. 45, pp. 14964–14971, 2010.

[94] H. Y. He, W. Hodos, and E. M. Quinlan, “Visual deprivation reactivates rapid ocular dominance plasticity in adult visual cortex,” *Journal of Neuroscience*, vol. 26, no. 11, pp. 2951–2955, 2006.
A. Bailey, A. Le Couteur, I. Gottesman et al., "Autism as a strongly genetic disorder: evidence from a British twin study," *Nature Neuroscience*, vol. 26, no. 3, pp. 570–571, 2004.

D. Carulli, T. Pizzorusso, J. C. F. Kwok et al., "Animals lacking link protein have attenuated perineuronal nets and persistent plasticity," *Brain*, vol. 133, no. 8, pp. 2331–2347, 2010.

A. W. McGee, Y. Yang, Q. S. Fischer, N. W. Daw, and S. H. Strittmatter, "Neuroscience: experience-driven plasticity of visual cortex limited by myelin and nogo receptor," *Science*, vol. 309, no. 5744, pp. 2222–2226, 2005.

H. Morishita, M. Chung, H. Miyamoto, Z. He, M. Fagioli, and T. K. Hensch, unpublished observations.

T. Pizzorusso, P. Medini, S. Landi, S. Baldini, N. Berardi, and L. Maffei, "Structural and functional recovery from early monocular deprivation in adult rats," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 22, pp. 8517–8522, 2006.

Y. Jiao, C. Zhang, Y. Yanagawa, and Q. Q. Sun, "Major effects of sensory experiences on the neocortical inhibitory circuits," *Journal of Neuroscience*, vol. 26, no. 34, pp. 8691–8701, 2006.

T. S. Balmer, V. M. Carels, J. L. Frisch, and T. A. Nick, "Modulation of perineuronal nets and parvalbumin with developmental song learning," *Journal of Neuroscience*, vol. 29, no. 41, pp. 12878–12885, 2009.

E. De Villers-Sidani, K. L. Simpson, Y. F. Lu, R. C. S. Lin, and M. M. Merzenich, "Manipulating critical period closure across different sectors of the primary auditory cortex," *Nature Neuroscience*, vol. 11, no. 8, pp. 957–965, 2008.

A. Bailey, A. Le Couteur, I. Gottesman et al., "Autism as a strongly genetic disorder: evidence from a British twin study," *Psychological Medicine*, vol. 25, no. 1, pp. 63–77, 1995.

C. Betancur, T. Sakurai, and J. D. Buxbaum, "The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders," *Trends in Neurosciences*, vol. 32, no. 7, pp. 402–412, 2009.

E. C. Budreck and P. Scheiffele, "Neuroligin-3 is a neuronal adhesion protein at GABAergic and glutamatergic synapses," *European Journal of Neuroscience*, vol. 26, no. 7, pp. 1738–1748, 2007.

S. Jamain, H. Quach, C. Betancur et al., "Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism," *Nature Genetics*, vol. 34, no. 1, pp. 27–29, 2003.

C. M. Durand, C. Betancur, T. M. Boeckers et al., "Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders," *Nature Genetics*, vol. 39, no. 1, pp. 25–27, 2007.

R. Moessner, C. R. Marshall, J. S. Sutcliffe et al., "Contribution of SHANK3 mutations to autism spectrum disorder," *American Journal of Human Genetics*, vol. 81, no. 6, pp. 1289–1297, 2007.

J. Gauthier, D. Spiegelman, A. Piton et al., "Novel de novo SHANK3 mutation in autistic patients," *American Journal of Medical Genetics, Part B*, vol. 150, no. 3, pp. 421–424, 2009.

R. J. Delahanty, J. Q. Kang, C. W. Brune et al., "Maternal transmission of a rare GABRB3 signal peptide variant is associated with autism," *Molecular Psychiatry*, vol. 16, no. 1, pp. 86–96, 2011.

International Molecular Genetic Study of Autism Consortium (IMGSAC), "A genomewide screen for autism: Strong evidence for linkage to chromosomes 2q, 7q, and 16p: international molecular genetic study of autism consortium, (IMGSAC)," *American Journal of Human Genetics*, vol. 69, no. 3, pp. 570–581, 2001.

D. A. Skaar, Y. Shao, J. L. Haines et al., "Analysis of the RELN gene as a genetic risk factor for autism," *Molecular Psychiatry*, vol. 10, no. 6, pp. 563–571, 2005.

F. Laumonnier, F. Bonnet-Brilhaut, M. Gomot et al., "X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family," *American Journal of Human Genetics*, vol. 74, no. 3, pp. 552–557, 2004.

C. R. Marshall, A. Noor, J. B. Vincent et al., "Structural variation in chromosomes in autism spectrum disorder," *American Journal of Human Genetics*, vol. 82, no. 2, pp. 477–488, 2008.

Autism Genome Project Consortium, "Mapping autism risk loci using genetic linkage and chromosomal rearrangements," *Nature Genetics*, vol. 39, pp. 319–328, 2007.

J. T. Glessner, K. Wang, G. Cai et al., "Autism genomewide copy number variation reveals ubiquitin and neuronal genes," *Nature*, vol. 459, no. 7246, pp. 569–572, 2009.

H. G. Kim, S. Kishikawa, A. W. Higgins et al., "Disruption of neurexin 1 associated with autism spectrum disorder," *American Journal of Human Genetics*, vol. 82, no. 1, pp. 199–207, 2008.

D. Dhossche, H. Applegate, A. Abraham et al., "Elevated plasma gamma-aminobutyric acid (GABA) levels in autistic youngsters: Stimulus for a GABA hypothesis of autism," *Medical Science Monitor*, vol. 8, no. 6, pp. PR1–PR6, 2002.

D. M. Dhossche, Y. Song, and Y. Liu, "Is there a connection between autism, Prader-Willi syndrome, catatonia, and GABA?" *International Review of Neurobiology*, vol. 71, pp. 189–216, 2005.

S. H. Fatemi, A. R. Halt, J. M. Stary, R. Kanodia, S. C. Schulz, and G. R. Realmuto, "Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices," *Biological Psychiatry*, vol. 52, no. 8, pp. 805–810, 2002.

J. Yip, J. J. Soghomonian, and G. J. Blatt, "Decreased GAD67 mRNA levels in cerebellar Purkinje cells in autism: pathophysiological implications," *Acta Neuropathologica*, vol. 113, no. 5, pp. 539–568, 2007.

A. L. Collins, D. Ma, P. L. Whitehead et al., "Investigation of autism and GABA receptor subunit genes in multiple ethnic groups," *Neurogenetics*, vol. 7, no. 3, pp. 167–174, 2006.

S. H. Fatemi, T. D. Folsom, T. J. Reutiman, and P. D. Thuras, "Expression of GABAB receptors is altered in brains of subjects with autism," *Cerebellum*, vol. 8, no. 1, pp. 64–69, 2009.
Neural Plasticity

[128] S. H. Fatemi, T. J. Reutiman, T. D. Folsom, and P. D. Thuras, “GABAA receptor downregulation in brains of subjects with autism," Journal of Autism and Developmental Disorders, vol. 39, no. 2, pp. 223–230, 2009.

[129] S. H. Fatemi, T. J. Reutiman, T. D. Folsom, R. J. Rooney, D. H. Patel, and P. D. Thuras, “mRNA and protein levels for GABA A 4, 6, and 1 receptors are altered in brains from subjects with autism," Journal of Autism and Developmental Disorders, vol. 40, no. 6, pp. 743–750, 2010.

[130] J. T. Gupill, A. B. Booker, T. T. Gibbs, T. L. Kemper, M. L. Bauman, and G. J. Blatt, “3H-flunitrazepam-labeled benzodiazepine binding sites in the hippocampal formation in autism: a multiple concentration autoradiographic study," Journal of Autism and Developmental Disorders, vol. 37, no. 5, pp. 911–920, 2007.

[131] M. F. Casanova, D. P. Buxhoeveden, A. E. Switala, and E. Roy, “Minicolumnar pathology in autism," Neurology, vol. 58, no. 3, pp. 428–432, 2002.

[132] M. F. Casanova, D. Buxhoeveden, and J. Gomez, “Disruption in the inhibitory architecture of the cell minicolumn: implications for autism," Neuroscientist, vol. 9, no. 6, pp. 496–507, 2003.

[133] J. I. Hutsler and H. Zhang, “Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders," Brain Research, vol. 1309, pp. 83–94, 2010.

[134] C. Gillberg and E. Billstedt, “Autism and Asperger syndrome: coexistence with other clinical disorders," Acta Psychiatrica Scandinavica, vol. 102, no. 5, pp. 321–330, 2000.

[135] R. E. Amir, I. B. Van Den Veyver, M. Wan, C. Q. Tran, U. Francke, and H. Y. Zoghbi, “Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2," Nature Genetics, vol. 23, no. 2, pp. 185–188, 1999.

[136] S. J. Moser, P. Weber, and J. Lütschg, “Rett syndrome: clinical and electrophysiologic aspects," Pediatric Neurology, vol. 36, no. 2, pp. 95–100, 2007.

[137] P. V. Belichenko, A. Oldfors, B. Hagberg, and A. Dahlstrom, “Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents," NeuroReport, vol. 5, no. 12, pp. 1509–1513, 1994.

[138] C. A. Chapleau, G. D. Calfa, M. C. Lane et al., “Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations," Neurobiology of Disease, vol. 35, no. 2, pp. 219–233, 2009.

[139] M. E. Blue, S. Naidu, and M. V. Johnston, “Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome," Experimental Neurology, vol. 156, no. 2, pp. 345–352, 1999.

[140] R. C. Samaco, A. Hogart, and J. M. LaSalle, “Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MEC2 deficiency causes reduced expression of UBE3A and GABRB3," Human Molecular Genetics, vol. 14, no. 4, pp. 483–492, 2005.

[141] W. G. Chen, Q. Chang, Y. Lin et al., “Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2," Science, vol. 302, no. 5646, pp. 885–889, 2003.

[142] K. Martinowich, D. Hattori, H. Wu et al., “DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation," Science, vol. 302, no. 5646, pp. 890–893, 2003.

[143] M. Chahrouf and H. Y. Zoghbi, “The story of Rett syndrome: from clinic to neurobiology," Neuron, vol. 56, no. 3, pp. 422–437, 2007.

[144] D. Tropea, E. Giacometti, N. R. Wilson et al., “Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 6, pp. 2029–2034, 2009.

[145] A. J. M. H. Verkerk, M. Pieretti, J. S. Sutcliffe et al., “Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome," Cell, vol. 65, no. 5, pp. 905–914, 1991.

[146] V. J. Hinton, W. T. Brown, K. Wisniewski, and R. D. Rudelli, “Analysis of neocortex in three males with the fragile X syndrome," American Journal of Medical Genetics, vol. 41, no. 3, pp. 289–294, 1991.

[147] S. A. Irwin, R. Galvez, and W. T. Greenough, “Dendritic spine structural anomalies in fragile-X mental retardation syndrome," Cerebral Cortex, vol. 10, no. 10, pp. 1038–1044, 2000.

[148] M. F. Bear, K. M. Huber, and S. T. Warren, “The mGluR theory of fragile X mental retardation," Trends in Neurosciences, vol. 27, no. 7, pp. 370–377, 2004.

[149] S. Jacquemont, A. Curie, V. Des Portes et al., “Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056," Science Translational Medicine, vol. 3, no. 64, Article ID 64ra1, 2011.

[150] A. Sarthi, B. Jiang, A. Komaki, K. Sohya, Y. Yanagawa, and T. Tsumoto, “Metabotropic glutamate receptor type 5-dependent long-term potentiation of excitatory synapses on fast-spiking GABAergic neurons in mouse visual cortex," Journal of Neuroscience, vol. 28, no. 5, pp. 1224–1235, 2008.

[151] J. R. Gibson, A. F. Bartley, S. A. Hays, and K. M. Huber, “Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome," Journal of Neurophysiology, vol. 100, no. 5, pp. 2615–2626, 2008.

[152] C. D’Hulst and R. F. Kooy, “The GABA A receptor: a novel target for treatment of fragile X?" Trends in Neurosciences, vol. 30, no. 8, pp. 425–431, 2007.

[153] J. Clayton-Smith and L. Laan, “Angelman syndrome: a review of the clinical and genetic aspects," Journal of Medical Genetics, vol. 40, no. 2, pp. 87–95, 2003.

[154] P. L. Greer, R. Hanayama, B. L. Bloodgood et al., “The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc," Cell, vol. 140, no. 5, pp. 704–716, 2010.

[155] B. A. Minassian, T. M. DeLorey, R. W. Olsen et al., “Angelman syndrome: correlations between epilepsy phenotypes and genotypes," Annals of Neurology, vol. 43, no. 4, pp. 485–493, 1998.

[156] W. H. Roden, L. D. Peugh, and L. A. Jansen, “Altered GABA receptor subunit expression and pharmacology in human Angelman syndrome cortex," Neuroscience Letters, vol. 483, no. 3, pp. 167–172, 2010.

[157] M.A. Geyer and A. Markou, "Animal models of psychiatric disease," in Psychopharmacology: The Fourth Generation of Progress, pp. 787–798, Raven Press, New York, NY, USA, 1995.

[158] J. N. Crawley, “Designing mouse behavioral tasks relevant to autistic-like behaviors," Mental Retardation and Developmental Disabilities Research Reviews, vol. 10, no. 4, pp. 248–258, 2004.

[159] D. Comoletti, A. De Jaco, L. L. Jennings et al., “The Arg451Cys-neuroligin-3 mutation associated with autism..."
reveals a defect in protein processing," *Journal of Neuroscience*, vol. 24, no. 20, pp. 4889–4893, 2004.

[160] A. A. Chubykin, X. Liu, D. Comoletti, I. Tsigelny, P. Taylor, and T. C. Südhof, "Dissection of synapse induction by neurelins: effect of a neurelin mutation associated with autism," *Journal of Biological Chemistry*, vol. 280, no. 23, pp. 22365–22374, 2005.

[161] K. Tabuchi, J. Blundell, M. R. Etherton et al., "A neurelin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice," *Science*, vol. 318, no. 5847, pp. 71–76, 2007.

[162] K. K. Chadman, S. Gong, M. L. Scattoni et al., "Minimal aberrant behavioral phenotypes of neurelin-3 R451C knockin mice," *Autism Research*, vol. 1, no. 3, pp. 147–158, 2008.

[163] Y.-B. Choi, H.-L. Li, S. Kassabov et al., "Neurexin-neurelin transsynaptic interaction mediates learning-related synaptic remodeling and long-term facilitation in aplysia," *Neuron*, vol. 70, no. 3, pp. 468–481, 2011.

[164] S. Jamain, K. Radyushkin, K. Hammerschmidt et al., "Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 5, pp. 1710–1715, 2008.

[165] J. Peça, C. Feliciano, J. T. Ting et al., "Shank3 mutant mice display autistic-like behaviours and striatal dysfunction," *Nature*, vol. 472, no. 7344, pp. 437–442, 2011.

[166] C. Prasad, A. N. Prasad, B. N. Chodirker et al., "Genetic evaluation of pervasive developmental disorders: the terminal 22q13 deletion syndrome may represent a recognizable phenotype," *Clinical Genetics*, vol. 57, no. 2, pp. 103–109, 2000.

[167] H. L. Wilson, A. C. C. Wong, S. R. Shaw et al., "Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms," *Journal of Medical Genetics*, vol. 40, no. 8, pp. 575–584, 2003.

[168] A. L. Christianson, N. Chesler, and J. G. R. Kromberg, "Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs," *Developmental Medicine and Child Neurology*, vol. 36, no. 4, pp. 361–369, 1994.

[169] P. G. Williams and J. H. Hersh, "A male with fetal valproate syndrome and autism," *Developmental Medicine and Child Neurology*, vol. 39, no. 9, pp. 632–634, 1997.

[170] G. Williams, J. King, M. Cunningham, M. Stephan, B. Kerr, and J. H. Hersh, "Fetal valproate syndrome and autism: additional evidence of an association," *Developmental Medicine and Child Neurology*, vol. 43, no. 3, pp. 202–206, 2001.

[171] R. L. Bromley, G. Mawer, J. Clayton-Smith, and G. A. Baker, "Autism spectrum disorders following in utero exposure to antiepileptic drugs," *Neurology*, vol. 71, no. 23, pp. 1923–1924, 2008.

[172] S. S. Moy and J. J. Nadler, "Advances in behavioral genetics: mouse models of autism," *Molecular Psychiatry*, vol. 13, no. 1, pp. 4–26, 2008.

[173] H. Markram, T. Rinaldi, and K. Markram, "The intense world syndrome—an alternative hypothesis for autism," *Frontiers in Neuroscience*, vol. 1, pp. 77–96, 2007.

[174] T. Rinaldi, K. Kulangara, K. Antoniello, and H. Markram, "Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 33, pp. 13501–13506, 2007.

[175] T. Rinaldi, C. Perrodin, H. Markram, B. Cauli, and U. Pierre, "Hyper-connectivity and hyper-plasticity in the medial prefrontal cortex in the valproic acid animal model of autism," *Frontiers in Neural Circuits*, vol. 2, pp. 1–7, 2008.

[176] T. Rinaldi, G. Silberberg, and H. Markram, "Hyperconnectivity of local neocortical microcircuitry induced by prenatal exposure to valproic acid," *Cerebral Cortex*, vol. 18, no. 4, pp. 763–770, 2008.

[177] H. G. McFarlane, G. K. Kusek, M. Yang, J. L. Phoenix, V. J. Bolivar, and J. N. Crawley, "Autism-like behavioral phenotypes in BTBR T+tf/J mice," *Genes, Brain and Behavior*, vol. 7, no. 2, pp. 152–163, 2008.

[178] M. L. Scattoni, S. U. Gandhy, L. Ricceri, and J. N. Crawley, "Unusual repertoire of vocalizations in the BTBR T+tf/J mouse model of autism," *PloS One*, vol. 3, no. 8, Article ID e3067, 2008.

[179] J. L. Silverman, S. S. Tolu, C. L. Barkan, and J. N. Crawley, "Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP," *Neuropsychopharmacology*, vol. 35, no. 4, pp. 976–989, 2010.

[180] K. K. Chadman, "Fluoxetine but not risperidone increases sociability in the BTBR mouse model of autism," *Pharmacology Biochemistry and Behavior*, vol. 97, no. 3, pp. 586–594, 2011.

[181] M. E. Bear, G. Dölen, E. Osterweil, and N. Nagarajan, "Fragment X: translation in action," *Neuropsychopharmacology*, vol. 33, no. 1, pp. 84–87, 2008.

[182] F. M. S. de Vrij, J. Levenga, H. C. van der Linde et al., "Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice," *Neurobiology of Disease*, vol. 31, no. 1, pp. 127–132, 2008.

[183] G. Dölen and M. F. Bear, "Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome," *Journal of Physiology*, vol. 586, no. 6, pp. 1503–1508, 2008.

[184] Q. J. Yan, M. Rammal, M. Tranfaglia, and R. P. Bauchwitz, "Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP," *Neuropsychopharmacology*, vol. 49, no. 7, pp. 1053–1066, 2005.

[185] R. Z. Chen, S. Akbarian, M. Tudor, and R. Jaenisch, "Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice," *Nature Genetics*, vol. 27, no. 3, pp. 327–331, 2001.

[186] J. Guy, B. Hendrich, M. Holmes, J. E. Martin, and A. Bird, "A mouse MeCP2-null mutation causes neurological symptoms that mimic Rett syndrome," *Nature Genetics*, vol. 27, no. 3, pp. 322–326, 2001.

[187] M. D. Shahbazian, J. I. Young, L. A. Yuva-Paylor et al., "Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3," *Neuron*, vol. 35, no. 2, pp. 243–254, 2002.

[188] J. D. Picker, R. Yang, L. Ricceri, and J. Berger-Sweeney, "An altered neonatal behavioral phenotype in Mecp2 mutant mice," *NeuroReport*, vol. 17, no. 5, pp. 541–544, 2006.

[189] P. Moretti, J. A. Bouwknecht, R. Teague, R. Paylor, and H. Y. Zoghbi, "Abnormalities of social interactions and homecage behavior in a mouse model of Rett syndrome," *Human Molecular Genetics*, vol. 14, no. 2, pp. 205–220, 2005.

[190] T. Gemelli, O. Berton, E. D. Nelson, L. I. Perrotti, R. Jaenisch, and L. M. Monteggia, "Postnatal loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate behavioral aspects of Rett syndrome in mice," *Biological Psychiatry*, vol. 59, no. 5, pp. 468–476, 2006.
[191] P. Moretti, J. M. Levenson, F. Battaglia et al., “Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome,” Journal of Neuroscience, vol. 26, no. 1, pp. 319–327, 2006.

[192] V. S. Dani, Q. Chang, A. Maffei, G. G. Turrigiano, R. Jaenisch, and S. B. Nelson, “Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett Syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 35, pp. 12560–12565, 2005.

[193] V. S. Dani and S. B. Nelson, “Intact long-term potentiation but reduced connectivity between neocortical layer 5 pyramidal neurons in a mouse model of Rett syndrome,” Journal of Neuroscience, vol. 29, no. 36, pp. 11263–11270, 2009.

[194] L. Medrihan, E. Tantalaki, G. Aramuni et al., “Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome,” Journal of Neurophysiology, vol. 99, no. 1, pp. 112–121, 2008.

[195] H. T. Chao, H. Chen, R. C. Samaco et al., “Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes,” Nature, vol. 468, no. 7321, pp. 263–269, 2010.

[196] S. Cobb, J. Guy, and A. Bird, “Reversibility of functional deficits in experimental models of Rett syndrome,” Biochemical Society Transactions, vol. 38, no. 2, pp. 498–506, 2010.

[197] C. E. Bakker, C. Verheij, R. Willemsen et al., “Fmr1 knockout mice: a model to study fragile X mental retardation,” Cell, vol. 78, no. 1, pp. 23–33, 1994.

[198] C. L. Gatto, K. Broadie, and H. Cline, “Genetic controls balancing excitatory and inhibitory synaptogenesis in neurodevelopmental disorder models,” Frontiers in Synaptic Neuroscience, vol. 2, pp. 1–19, 2010.

[199] Y. H. Jiang, D. Armstrong, U. Albrecht et al., “Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation,” Neuron, vol. 21, no. 4, pp. 799–811, 1998.

[200] K. Miura, T. Kishino, E. Li et al., “Neurobehavioral and electroencephalographic abnormalities in Ube3a maternal-deficient mice,” Neurobiology of Disease, vol. 9, no. 2, pp. 149–159, 2002.

[201] E. J. Weeber, Y. H. Jiang, Y. Elgersma et al., “Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome,” Journal of Neuroscience, vol. 23, no. 7, pp. 2634–2644, 2003.

[202] K. Yashiro, T. T. Riday, K. H. Condon et al., “Ube3a is required for experience-dependent maturation of the neocortex,” Nature Neuroscience, vol. 12, no. 6, pp. 777–783, 2009.

[203] G. E. Homanics, T. M. DeLorey, L. L. Firestone et al., “Mice devoid of γ-aminobutyrate type A receptor β3 subunit have epilepsy, cleft palate, and hypersensitive behavior,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 8, pp. 4143–4148, 1997.

[204] T. M. DeLorey, A. Handforth, S. G. Anagnostaras et al., “Mice lacking the β3 subunit of the GABA(A) receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome,” Journal of Neuroscience, vol. 18, no. 20, pp. 8505–8514, 1998.

[205] S. T. Sinkkonen, G. E. Homanics, and E. R. Korpi, “Mouse models of Angelman syndrome, a neurodevelopmental disorder, display different brain regional GABAA receptor alterations,” Neuroscience Letters, vol. 340, no. 3, pp. 205–208, 2003.